Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS
Neurology and Therapy · 2025-08 · 14 (4) · 1345-1353
DOI: 10.1007/s40120-025-00736-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 12.05.2025. Verfasst von Aurora Zanghì und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Foggia, Viale L Pinto 1, CAP 71122, Foggia, Italy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: Cognitive dysfunction represents a major burden in multiple sclerosis (MS). The impact on cognitive outcomes of ozanimod in real-world settings remains to be fully elucidated. METHODS: In this single-center observational study, we evaluated cognitive performance in 67 patients with MS (74.6% female) receiving ozanimod (mean treatment duration 17.7 ± 3.0 months). Cognitive assessment was performed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery, comprising Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-II (CVLT-II), and Brief Visuospatial Memory Test-Revised (BVMT-R) collected at different time points. RESULTS: Analysis suggested significant improvement in SDMT Z-scores (mean improvement 0.337, SD 0.638; Cohen's d = 0.42, p = 0.00031). Baseline SDMT Z-score emerged as the sole significant predictor of cognitive change (coefficient - 0.345, p < 0.001), accounting for 32.4% of variance. CVLT-II and BVMT-R scores remained stable across time points. CONCLUSIONS: This real-world study suggests that ozanimod treatment is associated with significant improvement in information processing speed, independent of traditional prognostic factors. These findings complement existing clinical trial data and warrant further investigation through larger, multicenter studies with extended follow-up periods to validate these cognitive benefits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Foggia, Viale L Pinto 1, CAP 71122, Foggia, Italy.
- Department of Medical and Surgical Sciences, University of Foggia, Viale L Pinto 1, CAP 71122, Foggia, Italy. emanuele.damico@unifg.it.
Zitieren
APA
Zanghì, A., Di Filippo, P. S., Avolio, C., & D'Amico, E. (2025). Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS. Neurology and Therapy, 14(4), 1345-1353. https://doi.org/10.1007/s40120-025-00736-8
Vancouver
Zanghì A, Di Filippo PS, Avolio C, D'Amico E. Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS. Neurology and Therapy. 2025;14(4):1345-1353. doi:10.1007/s40120-025-00736-8
BibTeX
@article{Zangh2025,
author = {Zanghì, Aurora and Di Filippo, Paola Sofia and Avolio, Carlo and D'Amico, Emanuele},
title = {Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS},
journal = {Neurology and Therapy},
year = {2025},
volume = {14},
number = {4},
pages = {1345--1353},
doi = {10.1007/s40120-025-00736-8}
}
EUVIMED